

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK COUNTY

BOARD OF REGISTRATION  
IN PHARMACY

In the Matter of )  
CVS # 166 )  
DS3449 )

PHA-2019-0079

CONSENT AGREEMENT FOR PROBATION

The Massachusetts Board of Registration in Pharmacy ("Board") and CVS # 166 ("Licensee" or "Pharmacy"), a pharmacy licensed by the Board, DS3449, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Pharmacy's record maintained by the Board:

1. The Pharmacy acknowledges the Board opened a complaint against its pharmacy license related to the conduct set forth in Paragraph 2, identified as Docket No. PHA-2019-0079 ("the Complaint").<sup>1</sup>
2. The Board and the Licensee acknowledge and agree to the following facts:
  - a. On or about February 12, 2019, the Pharmacy lost approximately # 327 carisoprodol 350 mg tablets. The Pharmacy's investigation did not determine the cause of the loss of said carisoprodol.
  - b. The foregoing facts warrant action by the Board under M.G.L. c. 112, §§ 42A and 61 and under 247 CMR 10.03(1)(v).
3. Additionally, the Board and Licensee acknowledge and agree to the following facts regarding previous complaints against the Pharmacy's license:
  - a. Complaint PHA-2016-0157: On or about June 3, 2016, the Pharmacy discovered it lost # 802 zolpidem tartrate 10 mg tablets. The Pharmacy could not determine the cause of the loss of said zolpidem.

<sup>1</sup> The term "License" applies to both a current license and the right to renew an expired license.

CVS # 166  
DS3449  
PHA-2019-0079

- b. Complaint PHA-2017-0178: On or about July 10, 2017, the Pharmacy lost approximately # 1,054 tramadol 50 mg tablets. The Pharmacy could not determine the cause of the loss of said tramadol. Additionally, on or about September 5, 2017, the Pharmacy lost approximately # 464 lorazepam 1 mg tablets. The Pharmacy could not determine the cause of the loss of said lorazepam.
4. The Pharmacy agrees that its license shall be placed on PROBATION for one (1) year ("Probationary Period"), commencing with the date on which the Board signs this Agreement ("Effective Date").
5. During the Probationary Period, the Pharmacy further agrees that it shall comply with all of the following requirements to the Board's satisfaction:
- a. Comply with all laws and regulations governing the practice of pharmacy in Massachusetts.
  - b. Within 30 days from Effective Date, conduct an exact count of all controlled substances in Schedules III - V. The Pharmacy shall maintain documentation of the exact counts. Said documentation shall be available for review by Board investigators during the Probationary Period.
  - c. Conduct an exact count of all carisoprodol, benzodiazepine, tramadol, and gabapentin products at least once every 30 days for a period of one year following the Effective Date. The Pharmacy shall maintain documentation of the exact counts. Said documentation shall be available for review by Board investigators during the Probationary Period.
  - d. Submit documentation demonstrating all staff were retrained in areas of inventory management, prescription production, and waiting bin management within 30 days from the Effective Date.

CVS # 166  
DS3449  
PHA-2019-0079

- e. Maintain documentation demonstrating the area pharmacy supervisor or loss prevention manager reviewed the Pharmacy's balance on hand modification cover pages for all carisoprodol, benzodiazepine, tramadol, and gabapentin products at least once every 30 days for a period of one year following the Effective Date. Said documentation shall be available for review by Board investigators during the Probationary Period.
6. The Board agrees that in return for the Pharmacy's execution and its successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
7. If the Pharmacy has complied to the Board's satisfaction with all the requirements contained in this Agreement, the Probationary Period will terminate one (1) year after the Effective Date upon written notice to the Pharmacy from the Board<sup>2</sup>.
8. If the Pharmacy does not materially comply with each requirement of this Agreement, or if the Board opens a Subsequent Complaint<sup>3</sup> during the Probationary Period, the Pharmacy agrees to the following:
- c. The Board may upon written notice to the Pharmacy, as warranted to protect the public health, safety, or welfare:
- i. EXTEND the Probationary Period;
  - ii. MODIFY the Probation Agreement requirements; or
  - iii. IMMEDIATELY SUSPEND the Pharmacy's license.
- d. If the Board suspends the Pharmacy's license pursuant to Paragraph 8(a)(iii), the suspension shall remain in effect until:
- i. the Board provides the Pharmacy written notice that the Probationary Period is to be resumed and under what terms;
  - ii. the Board and the Pharmacy sign a subsequent agreement; or


<sup>2</sup> In all instances where this Agreement specifies written notice to the Pharmacy from the Board, such notice shall be sent to the Pharmacy's address of record.

<sup>3</sup> The term "Subsequent Complaint" applies to a complaint opened after the Effective Date concerning acts, omissions, or events occurring after the Effective Date, which (1) alleges that the Pharmacy engaged in conduct that violates Board statutes or regulations, and (2) is substantiated by evidence, as determined following the complaint investigation during which the Pharmacy shall have an opportunity to respond.

- iii. the Board issues a written final decision and order following adjudication of the allegations (1) of noncompliance with this Agreement, and/or (2) contained in the Subsequent Complaint.
9. The Pharmacy agrees that if the Board suspends its license in accordance with Paragraph 8, it will immediately return its current Massachusetts license to the Board, by hand or certified mail. The Pharmacy further agrees that upon said suspension, it will no longer be authorized to operate as a pharmacy in the Commonwealth of Massachusetts and shall not in any way represent itself as a pharmacy until such time as the Board reinstates license or right to renew such license.
10. The Pharmacy understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication it would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, M.G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 et seq. The Pharmacy further understands that by executing this Agreement it is knowingly and voluntarily waiving its right to a formal adjudication of the Complaints.
11. The Pharmacy acknowledges that it has been at all times free to seek and use legal counsel in connection with the Complaint and this Agreement.
12. The Pharmacy acknowledges that after the Effective Date, the Agreement constitutes a public record. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
13. The Pharmacy understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal, or judicial review.


CVS # 166  
DS3449  
PHA-2019-0079

14. The individual signing this Agreement certifies that he/she is authorized to enter into this Agreement on behalf of the Pharmacy, and that he/she has read this Agreement.



Witness (sign and date)

10/24/19



(sign and date)

10/24/19

Leo Lariviere

(print name)



David Sencabaugh, R. Ph.  
Executive Director  
Board of Registration in Pharmacy

11-4-19

Effective Date

Fully Signed Agreement Sent to Licensee on 11/7/19 by

Certified Mail No. 7019 0700 0000 1934 6347